QUANTITATIVE EPITOPE MAPPING OF IGA TO HIV GP120

说明：虽然取得了重大进展， HIV-1疫苗的开发，我们刚刚开始 在诱导粘膜免疫方面取得了进展。 一个主要限制 粘膜疫苗的发展一直很困难， 定量评价粘膜表面的免疫应答。 我们 我建议开发一种检测方法， 抗原决定簇特异性抗体我们假设 粘膜抗体的诱导可以使用 这种方法和信息将导致改善艾滋病毒-1 阻止感染传播的疫苗。 我们提出的 定量表位作图ELISA形式，或QEM ELISA，提供了一种 测定表位特异性抗体浓度的灵敏方法 抗体的该测定法可以容易地适用于分析样品， 广泛变化的抗体水平，包括血清，唾液，粪便， 尿液，对测定格式进行了微小修改。 该测定还可以 用于测量同种型特异性表位，而不需要消耗 样本中竞争性IG亚类或其他干扰物质。 从长远来看，QEM ELISA将广泛应用于 用于其它疾病（例如轮状病毒、RSV、流感、H.幽门， HPV等）。 拟议的商业应用：不可用。

DESCRIPTION: Although significant progress has been made in the development of an HIV-1 vaccine, we are just now beginning to make progress toward the induction of mucosal immunity. A major limitation on the development of mucosal vaccines has been difficulty in quantitatively evaluating the immune response at mucosal surfaces. We propose to develop an assay which will provide a quantitative measure of epitope specific antibodies at the mucosa. It is our hypothesis that the induction of mucosal antibodies can be accurately measured using this method and that the information will lead to improved HIV-1 vaccines that will block the spread of infection. Our proposed Quantitative Epitope Mapping ELISA format, or QEM ELISA, provides a sensitive way of measuring the concentration of epitope specific antibody. The assay can be easily adapted to analysis of samples with widely varying levels of antibody including serum, saliva, feces, and urine with minor modifications of the assay format. The assay can also be used to measure isotype specific epitopes without the need to deplete the sample for competing Ig subclasses or other interfering substances. Long term the QEM ELISA will have broad application to the analysis of vaccines for other disease (e.g. rotavirus, RSV, influenza, H. pylori, HPV, etc.). PROPOSED COMMERCIAL APPLICATION: Not available.